Advancements in Triglyceride-lowering Therapies: Insights from ESC 2024

In this course, recorded at ESC 2024 in London, Prof Gerald Watts (University of Western Australia, Perth, Australia) is joined by Prof Robert S Rosenson (Mount Sinai Icahn School of Medicine, New York, US) to discuss developments in triglyceride-lowering therapies.

The faculty consider triglycerides as a risk factor for cardiovascular disease and explore the relationship between triglycerides and the risk of acute pancreatitis and ASCVD. In addition, the series covers familial chylomicronemia syndrome (FCS), including the role of genetic testing to identify patients through risk assessment.

The faculty also review PALISADE, a phase 3 trial of investigational plozasiran in patients with diagnosed FCS, that concluded that patients with persistent chylomicronemia who received plozasiran had significantly lower triglyceride levels and incidence of pancreatitis than those who received placebo. Finally, the discussion centres on the potential diagnostic criteria for access to plozasiran.

This course is supported by an unrestricted educational grant from Arrowhead Pharmaceuticals.

In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the course are declared.

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the 'Faculty' section if applicable.

The course, ‘Advancements in Triglyceride-lowering Therapies: Insights from ESC 2024’, is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. 

There is no fee for taking part in this online learning activity.

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

To complete the course and claim certification participants must: 

• Read the course outline information supplied. Users must read and study the activity in its entirety before completing the post-test questions. 
• Your results will be automatically saved and if a pass score is achieved, you may be eligible to claim credit for the activity and receive a certificate of completion.